Quality Management BPI - New Contract

The current contract for Quality Management BPI is set to expire in September 2026, and the Food and Drug Administration (FDA) intends to request approval for a new contract to begin at that time. The planned contract will include a base year plus four option years, with an estimated total value of approximately $15 million, averaging about $3 million per year. Part of the funding for this new contract is expected to come from QMOE’s annual $1.5 million MDUFA V operational funds. This upcoming contract will continue to support the FDA’s quality management initiatives under NAICS code 561990. While specific details such as the solicitation number, contracting officer, and exact performance location are yet to be determined, the agency has designated the CDRH Acquisition Liaison as a primary point of contact. The procurement is listed as a forecast opportunity, with further information available through the FDA’s acquisition office.